Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies

Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies

Rationale & Objective: Epoetin alfa-epbx is a biosimilar to the reference product, epoetin alfa. We compare the safety of epoetin alfa-epbx versus epoetin alfa based on a pooled analysis of findings from 2 randomized, double-blind, comparative clinical studies, and report new data for the long-t...

Full description

Bibliographic Details
Main Authors:	Jay B. Wish, Marcelo G. Rocha, Nancy E. Martin, Christian Russel D. Reyes, Steven Fishbane, Mark T. Smith, George Nassar
Format:	Article
Language:	English
Published:	Elsevier 2019-09-01
Series:	Kidney Medicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2590059519300822

Similar Items

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
by: Steven Fishbane, et al.
Published: (2019-09-01)

The use of epoetin alfa biosimilar in the anemia management in hemodialysis patients
by: I. O. Dudar, et al.
Published: (2021-02-01)

Comparison Of The Effectiveness And Safety Of Anemia Epoetin Alfa With Epoetin Beta Inhemodialysis Routine Patients At Haji Rsu Surabaya
by: Gunawan Widodo, et al.
Published: (2021-12-01)

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
by: Bhanu Prasad, et al.
Published: (2020-06-01)

Darbepoetin versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
by: Pilar M Samper Ots, et al.
Published: (2008-01-01)

Shift in Balance of IV Iron-to-Epoetin USE: 2008-2011
by: Alex Yang, et al.
Published: (2012-06-01)

A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment
by: J Wilson, et al.
Published: (2007-04-01)

Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients
by: Amel Harzallah, et al.
Published: (2015-01-01)

Effect of Epoetin Alfa and Sodium Valproate in Patients with Myelodysplastic Syndrome
by: Seyed Ashkan Hosseini, et al.
Published: (2020-06-01)

Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open‐label, parallel‐group, noninferiority phase III trial
by: Bicheng Liu, et al.
Published: (2022-06-01)

Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail
by: Nan Chen, et al.
Published: (2022-03-01)

INFLUENCE OF EPOETIN ALFA ON LEVEL OF PROINFLAMMATORY AND ANTIINFLAMMATORY CYTOKINE OF PATIENTS IN MAINTENCE HEMODIALYSIS
by: I. Dudar, et al.
Published: (2014-03-01)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
by: Arrieta J, et al.
Published: (2014-10-01)

Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report
by: Behler Caroline M, et al.
Published: (2009-07-01)

Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study
by: E.J.F. Santos, et al.
Published: (2018-05-01)

THE COMPLEX INTENSIVE THERAPY INCLUDING APPLICATION EPOETIN ALFA AT THE SERIOUS СONCOMITANT BRAIN INJURY
by: E. A. Lebedeva, et al.
Published: (2013-03-01)

Own experience of treatment by epoetin-α (Eralfon®) of chemotherapy induced anemia
by: S A Bolshakova, et al.
Published: (2017-01-01)

Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease
by: Ohashi N, et al.
Published: (2012-03-01)

Race and Place in ESKD
by: Daniel J. Watford, et al.
Published: (2021-02-01)

Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study
by: Giovanni Rosti, et al.
Published: (2017-01-01)

THE CLINICAL EFFICACY OF EPOETIN ALFA AND DARBEPOETIN ALFA IN PATIENTS WITH LOW-RISK OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROME: RETROSPECTIVE MULTI-CENTER REAL-LIFE STUDY
by: Müzeyyen Aslaner Ak, et al.
Published: (2023-10-01)

Population Pharmacodynamic Modeling of Epoetin Alfa in End‐Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach
by: Ly Minh Nguyen, et al.
Published: (2020-10-01)

Epoetin alpha in the treatment of anemia in patients with malignant solid tumors during antitumor drug therapy
by: L. Yu. Vladimirova, et al.
Published: (2022-06-01)

Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
by: Davis-Ajami ML, et al.
Published: (2014-04-01)

Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease
by: Ken Aizawa, et al.
Published: (2018-01-01)

Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients
by: Shimamatsu K
Published: (2014-12-01)

S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
by: Matteo Giovanni Della Porta, et al.
Published: (2023-08-01)

ESKD in sub-Saharan Africa: will governments now listen?
by: Ikechi G Okpechi
Published: (2017-04-01)

Kidney Health Initiative ESKD Data Standards Project
by: Lorien S. Dalrymple, et al.
Published: (2022-08-01)

COVAN Leading to ESKD Despite Minimal COVID Symptoms
by: Dawn Maldonado MD, et al.
Published: (2022-04-01)

Fatigue visual analogue scale score correlates with quality of life in cancer patients receiving epoetin alfa (Sandoz) for chemotherapy-induced anaemia: The CIROCO study
by: Jerome Desramé, et al.
Published: (2023-01-01)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers
by: Yoon S, et al.
Published: (2017-10-01)

Potential cost saving of Epoetin alfa in elective hip or knee surgery due to reduction in blood transfusions and their side effects: a discrete-event simulation model.
by: Jörg Tomeczkowski, et al.
Published: (2013-01-01)

The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation
by: Sam Kant, et al.
Published: (2020-10-01)

Cohort Prospective Study to Evaluate Immunogenicity of Epodion® (Biosimilar Epoetin-α) in Anemia Associated with Chronic Kidney Disease (CKD) Patients
by: Nova Angginy, et al.
Published: (2022-07-01)

P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY
by: Uwe Platzbecker, et al.
Published: (2023-08-01)

Increasing access to integrated ESKD care as part of Universal Health Coverage
by: Jha, V, et al.
Published: (2019)

Risk of Progression to ESKD or Death in Adults With CKD: Three Paths Identified
by: Stuart L. Goldstein
Published: (2021-06-01)

Clinical Comparison of Renogen, a Biosimilar Epoetin-a, with the Originator, Eprex, in Chronic Kidney Disease Anemia in Indonesia: A Preliminary Study
by: Ni Made Hustrini, et al.
Published: (2019-11-01)

Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report
by: Tatsuyoshi Ikenoue, et al.
Published: (2017-10-01)